Studies are proposed on a recently identified, novel human kinase. The observations that it is mitogen-activated and nuclear-localized suggest it is a prime candidate to regulate transcription factors. Its activity is markedly and constitutively elevated in the peripheral blood lymphocytes of patients with acute leukemia. Purification and microsequencing indicate it is homologous to a Drosophila developmental regulator, fsh, known to activate the transcription factor, trithorax, and to a human gene of unknown function, RING3. Preliminary data reveal that RING3 interacts with ALL1, a human homolog of trithorax that has been linked to 11q23 acute leukemias. RING3 transforms NIH/3T3 cells, rendering them tumorigenic in nude mice, and can be activated by Ras and BCR-ABL. The applicant proposes to determine: (1) if RING3 phosphorylates and activates ALL-1; (2) how BCR-ABL and Ras activate RING3 kinase; (3) whether RING3 expression causes leukemia in transgenic mice and (4) the extent of the correlation between RING3 kinase activity and leukemia. The central hypothesis to be tested is that RING3 kinase is part of a signal transduction pathway that includes ALL-1 and is deregulated in leukemia.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
First Independent Research Support & Transition (FIRST) Awards (R29)
Project #
5R29CA075107-04
Application #
6173311
Study Section
Biological Sciences 2 (BIOL)
Program Officer
Mccarthy, Susan A
Project Start
1997-09-15
Project End
2002-09-29
Budget Start
2000-09-30
Budget End
2001-09-29
Support Year
4
Fiscal Year
2000
Total Cost
$119,282
Indirect Cost
Name
Boston University
Department
Type
Schools of Medicine
DUNS #
604483045
City
Boston
State
MA
Country
United States
Zip Code
02118
Chung, Jihyun; Karkhanis, Vrajesh; Tae, Sookil et al. (2013) Protein arginine methyltransferase 5 (PRMT5) inhibition induces lymphoma cell death through reactivation of the retinoblastoma tumor suppressor pathway and polycomb repressor complex 2 (PRC2) silencing. J Biol Chem 288:35534-47
Romesser, Paul B; Perlman, David H; Faller, Douglas V et al. (2009) Development of a malignancy-associated proteomic signature for diffuse large B-cell lymphoma. Am J Pathol 175:25-35
Wang, Fangnian; Liu, Hongsheng; Blanton, Wanda P et al. (2009) Brd2 disruption in mice causes severe obesity without Type 2 diabetes. Biochem J 425:71-83
Longe, Harold O; Romesser, Paul B; Rankin, Andrew M et al. (2009) Telomere homolog oligonucleotides induce apoptosis in malignant but not in normal lymphoid cells: mechanism and therapeutic potential. Int J Cancer 124:473-82
Lenburg, Marc E; Sinha, Anupama; Faller, Douglas V et al. (2007) Tumor-specific and proliferation-specific gene expression typifies murine transgenic B cell lymphomagenesis. J Biol Chem 282:4803-11
Denis, Gerald V; McComb, Mark E; Faller, Douglas V et al. (2006) Identification of transcription complexes that contain the double bromodomain protein Brd2 and chromatin remodeling machines. J Proteome Res 5:502-11
Greenwald, Rebecca J; Tumang, Joseph R; Sinha, Anupama et al. (2004) E mu-BRD2 transgenic mice develop B-cell lymphoma and leukemia. Blood 103:1475-84